In a post-pandemic world, the evolving landscape of clinical trials just got more complex. The year 2022 was one of many adjustments given the incidence of lower trial initiations. The health care industry endured the impacts of geopolitical conflicts, curbed growth in China and stagflation in major markets.

Pent-up trial demand during 2020 plus trial modernization strategies yields bumper performance in 2021 as research priorities revert to pre-pandemic trends.